JIR
KNSA icon

James Investment Research’s Kiniksa Pharmaceuticals KNSA Stock Holding History

James Investment Research’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$338K Hold
7,027
– – 0.04% 287
2025
Q4 		$290K Hold
7,027
– – 0.03% 302
2025
Q3 		$273K Buy
+7,027
New +$228K 0.03% 301
2023
Q2 		– Sell
-4,118
Closed -$44K – 420
2023
Q1 		$44K Buy
+4,118
New +$54.3K 0.01% 372

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

James Investment Research's KNSA Position: Q1 2026 in Review

James Investment Research held its Kiniksa Pharmaceuticals (KNSA) position steady in Q1 2026 at 7,027 shares worth $338K. The position accounts for 0.04% of the portfolio, ranked #287.

James Investment Research first reported a position in KNSA in Q1 2023 and has held it in 4 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • James Investment Research held 7,027 shares of Kiniksa Pharmaceuticals worth $338K as of Q1 2026.
  • James Investment Research left its Kiniksa Pharmaceuticals share count unchanged in Q1 2026.
  • Kiniksa Pharmaceuticals made up 0.04% of James Investment Research's portfolio in Q1 2026, its #287 holding.
  • James Investment Research first reported a position in Kiniksa Pharmaceuticals in Q1 2023 and has held it in 4 quarters since.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on James Investment Research's 13F filing for Q1 2026, filed 24 Apr 2026.